PANTHERx® Rare Announces Release of CUVRIOR™ (trientine tetrahydrochloride) to Treat Wilson Disease

PANTHERx® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to announce the launch of CUVRIOR to treat stable Wilson Disease in adults who are de-coppered and able to take penicillamine.

Scroll to Top